Business Context and Reporting Period
This Form 8-K is filed by Helius Medical Technologies, Inc. (not Solana Co) on August 9, 2024. The filing addresses a regulatory notice received from the Nasdaq Stock Market LLC regarding the company's compliance with listing standards.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only quantitative metric disclosed is the stock price performance:
- Stock Price: The closing bid price of Class A common stock was below $1.00 per share for the prior 30 consecutive business days.
- Trading Symbol: HSDT (Nasdaq Capital Market).
Material Changes
The material event reported is the receipt of a formal notice of non-compliance with Nasdaq Marketplace Rule 5550(a)(2) (Minimum Bid Price Requirement). This deficiency is solely based on the sustained low stock price over the preceding 30-day period.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has 180 calendar days (until February 5, 2025) to regain compliance.
- Remediation Path: Compliance is achieved if the stock closes at or above $1.00 for 10 consecutive business days.
- Extension Option: If the initial period expires without compliance, the company may qualify for an additional 180-day period if it meets other listing standards (e.g., market value of publicly held shares).
- Risks: Failure to regain compliance could result in delisting. The company explicitly states there is no assurance it will regain compliance or secure an extension.
- Management Action: The company intends to actively monitor the stock price and consider available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of HSDT to assess proximity to the $1.00 threshold.
- Monitor the company's stock price for 10 consecutive days to determine if the initial compliance window is met.
- Review the company's market value of publicly held shares to assess eligibility for a potential second compliance period.
- Check for any future 8-K filings regarding stock splits or other corporate actions intended to address the bid price deficiency.